SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The community is debating a campaign promise to issue a five-thousand-dollar dividend to every adult citizen, with critics dismissing the proposal as an unsubstantiated bribe that would exacerbate national debt and inflation. Discussion remains highly polarized, as supporters defend the economic strategy while detractors highlight its potential fiscal impact and the absence of similar past promises coming to fruition.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Traders are intensely debating the stock's downtrend, with many speculating about potential bankruptcy or further declines following its exclusion from the S&P 100 index. While some sentiment is driven by "go woke, go broke" criticism, others view the current price as a generational buying opportunity and anticipate a long-term turnaround.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple shares are reacting to the company's product launch, which introduced the foldable iPhone Duo starting at $1,999 and updated iPhone 18 Pro models. While the community is divided over whether the new hardware represents genuine innovation or a pricey, overdue response to competitors, many traders remain focused on potential sales performance and the impact on the stock's near-term volatility.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The community is debating the potential economic impact of a proposed dividend payment to U.S. citizens, with many traders expressing skepticism regarding its feasibility and inflationary risks. Markets are also showing caution ahead of key inflation data releases, as rising crude oil prices and Treasury yields continue to weigh on investor sentiment.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment shares are trending following a fiscal first-quarter earnings report that beat analyst expectations for revenue and earnings, bolstered by record funded backlog and strong demand for autonomous and laser weapon systems. While some traders expressed caution regarding the lack of raised full-year guidance and broader defense-sector volatility, sentiment remains largely bullish among those viewing the recent price pullback as a long-term accumulation opportunity.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as traders closely monitor rising Treasury yields and surging oil prices, with market sentiment heavily influenced by uncertainty surrounding upcoming inflation data and Federal Reserve policy. Discussions are dominated by intense debate over whether the market is being artificially supported by algorithmic intervention or if it remains resilient despite cooling breadth and persistent macroeconomic headwinds.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending following the licensing of its epilepsy drug, opakalim, to SK Biopharmaceuticals for up to $795 million. The deal provides significant non-dilutive cash to extend the company's runway while shifting development costs to the partner, allowing the community to shift focus toward upcoming obesity and degrader platform catalysts.

American Eagle Outfitters, Inc. operates retail stores and e-commerce channels offering apparel, accessories, and personal care products under the American Eagle and Aerie brands. It also operates the OFFL/NE by Aerie, Todd Snyder, and Unsubscribed brands. The firm operates stores in the United States, Canada, and Mexico and sells its products through international license partners. The company was founded in 1977 and is headquartered in Pittsburgh, PA.

American Eagle Outfitters Inc.

American Eagle Outfitters, Inc.

American Eagle Outfitters shares experienced a sharp decline following second-quarter earnings, as investors reacted negatively to a reliance on one-time tariff refunds and concerns over flat same-store sales guidance for the namesake brand. While some traders expressed frustration with the price drop despite a headline earnings beat, others view the pullback as an overreaction, pointing to momentum at the Aerie brand and potential holiday season recovery as catalysts for a rebound.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is currently experiencing downward price pressure and investor frustration following the recent release of its financial results, which included an earnings miss attributed to convertible note retirements. While some traders are highlighting the company's strong revenue growth and the long-term blockbuster potential of its lead assets like Recorlev and the upcoming Phase 3 trial for XP-8121, others are concerned about the extended 2030 timeline for the hypothyroidism candidate and are choosing to exit their positions.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are trending higher following positive commentary from the CFO regarding a significant expansion in the company's total addressable market for AI chips by 2030 and bullish price target revisions from analysts. While the community reaction is generally optimistic and focused on momentum, some traders express skepticism regarding the company's valuation and the sustainability of the current AI-driven rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

About 1 in 8 US adults is now on a GLP-1 weight-loss drug, w/ usage more than doubling since early 2024. As prices fall, the next wave of mass-market demand is imminent 
 
Recent FDA approval of Foundayo, Eli Lilly’s new once-daily oral weight-loss pill is priced aggressively at $149/month - t is roughly 85% cheaper than the initial list prices of injectable predecessors, moving GLP-1s from &quot;luxury tier&quot; to &quot;mass market&quot; 
 
A common side effect is fueling real demand for hair treatments, scalp serums &amp; supplements 
 
GLP-1s all list hair loss as a possible side effect. Doctors say it is tied to fast weight loss in general - less protein, fewer nutrients, more stress on the body - &amp; not the GLP-1 itself 
 
Circana ests GLP-1 households spend about +30% more on beauty products than non-GLP-1 households 
 
Hair treatment products take 3-6 months to show results. That makes the GLP-1 customer especially valuable to brands - this makes the GLP-1 user an &quot;anchor customer&quot; for brands, as they are statistically more likely to retest and reorder during their weight-loss journey 
 
Accenture&#39;s global beauty industry lead, called the size of the GLP-1 market &quot;unprecedented&quot; - money is flowing into pharma &amp; personal care companies trying to build new solutions 
 
Further, many users reduce their intake of certain foods (processed foods are seeing some of the steepest drops in demand), which has caused shifts in consumer behavior &amp; demand 
 
These households are shifting that budget toward high-protein dairy (+20%) and fresh produce (+55%) to combat muscle loss and nutrient gaps. 
 
JPMorgan ests 25M Americans will be on a GLP-1 by 2030 (up from 5M currently) - a 5x increase 
 
$LLY $NVO $ULTA $LRLCY $PBJ

Jim Rabe

Sanket N

FarUk

Pffffffffffffffffffffffffff

Cory D

alankr

StockTwits Web

Lilly(Eli) & Co

Novo Nordisk A/S

Ulta Beauty Inc

L'Oreal SA

Invesco Dynamic Food & Beverage ETF

About 1 in 8 US adults is now on a GLP-1 weight-loss drug, w/ usage more than doubling since early 2024. As prices fall, the next wave of mass-market demand is imminent 
 
Recent FDA approval of Foundayo, Eli Lilly’s new once-daily oral weight-loss pill is priced aggressively at $149/month - t is roughly 85% cheaper than the initial list prices of injectable predecessors, moving GLP-1s from "luxury tier" to "mass market" 
 
A common side effect is fueling real demand for hair treatments, scalp serums & supplements 
 
GLP-1s all list hair loss as a possible side effect. Doctors say it is tied to fast weight loss in general - less protein, fewer nutrients, more stress on the body - & not the GLP-1 itself 
 
Circana ests GLP-1 households spend about +30% more on beauty products than non-GLP-1 households 
 
Hair treatment products take 3-6 months to show results. That makes the GLP-1 customer especially valuable to brands - this makes the GLP-1 user an "anchor customer" for brands, as they are statistically more likely to retest and reorder during their weight-loss journey 
 
Accenture's global beauty industry lead, called the size of the GLP-1 market "unprecedented" - money is flowing into pharma & personal care companies trying to build new solutions 
 
Further, many users reduce their intake of certain foods (processed foods are seeing some of the steepest drops in demand), which has caused shifts in consumer behavior & demand 
 
These households are shifting that budget toward high-protein dairy (+20%) and fresh produce (+55%) to combat muscle loss and nutrient gaps. 
 
JPMorgan ests 25M Americans will be on a GLP-1 by 2030 (up from 5M currently) - a 5x increase 
 
